AAAAAA
Results: 1-25/62
Authors:
BHATARA VS
MAGNUS RD
PAUL KL
PRESKORN SH
Citation: Vs. Bhatara et al., SEROTONIN SYNDROME INDUCED BY VENLAFAXINE AND FLUOXETINE - A CASE-STUDY IN POLYPHARMACY AND POTENTIAL PHARMACODYNAMIC AND PHARMACOKINETIC MECHANISMS, The Annals of pharmacotherapy, 32(4), 1998, pp. 432-436
Authors:
HORST WD
PRESKORN SH
Citation: Wd. Horst et Sh. Preskorn, THE PHARMACOLOGY AND MODE OF ACTION OF VENLAFAXINE, Reviews in contemporary pharmacotherapy, 9(5), 1998, pp. 293-302
Authors:
UDDIN M
PRESKORN SH
Citation: M. Uddin et Sh. Preskorn, PHARMACODYNAMIC AND PHARMACOKINETIC FACTORS IN A CASE OF NEUROLEPTIC MALIGNANT SYNDROME, Journal of clinical psychopharmacology, 18(4), 1998, pp. 346-347
Authors:
PRESKORN SH
Citation: Sh. Preskorn, DEBATE RESOLVED - THERE ARE DIFFERENTIAL-EFFECTS OF SEROTONIN SELECTIVE REUPTAKE INHIBITORS ON CYTOCHROME-P450 ENZYMES, J PSYCHOPH, 12(3), 1998, pp. 89-97
Authors:
PRESKORN SH
Citation: Sh. Preskorn, CLINICALLY RELEVANT PHARMACOLOGY OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS - AN OVERVIEW WITH EMPHASIS ON PHARMACOKINETICS AND EFFECTS ON OXIDATIVE DRUG-METABOLISM, Clinical pharmacokinetics, 32, 1997, pp. 1-21
Authors:
PRESKORN SH
Citation: Sh. Preskorn, FOREWORD, Clinical pharmacokinetics, 32, 1997, pp. 6-6
Authors:
TREMAINE LM
WILNER KD
PRESKORN SH
Citation: Lm. Tremaine et al., A STUDY OF THE POTENTIAL EFFECT OF SERTRALINE ON THE PHARMACOKINETICSAND PROTEIN-BINDING OF TOLBUTAMIDE, Clinical pharmacokinetics, 32, 1997, pp. 31-36
Authors:
GARDNER MJ
BARIS BA
WILNER KD
PRESKORN SH
Citation: Mj. Gardner et al., EFFECT OF SERTRALINE ON THE PHARMACOKINETICS AND PROTEIN-BINDING OF DIAZEPAM IN HEALTHY-VOLUNTEERS, Clinical pharmacokinetics, 32, 1997, pp. 43-49
Authors:
ALDERMAN J
PRESKORN SH
GREENBLATT DJ
HARRISON W
PENENBERG D
ALLISON J
CHUNG M
Citation: J. Alderman et al., DESIPRAMINE PHARMACOKINETICS WHEN COADMINISTERED WITH PAROXETINE OR SERTRALINE IN EXTENSIVE METABOLIZERS, Journal of clinical psychopharmacology, 17(4), 1997, pp. 284-291
Authors:
SHAD MU
PRESKORN SH
Citation: Mu. Shad et Sh. Preskorn, A POSSIBLE BUPROPION AND IMIPRAMINE INTERACTION, Journal of clinical psychopharmacology, 17(2), 1997, pp. 118-119
Authors:
CATTERSON ML
PRESKORN SH
MARTIN RL
Citation: Ml. Catterson et al., PHARMACODYNAMIC AND PHARMACOKINETIC CONSIDERATIONS IN GERIATRIC PSYCHOPHARMACOLOGY, The Psychiatric clinics of North America, 20(1), 1997, pp. 205
Authors:
PRESKORN SH
Citation: Sh. Preskorn, SELECTION OF AN ANTIDEPRESSANT - MIRTAZAPINE, The Journal of clinical psychiatry, 58, 1997, pp. 3-8
Authors:
PRESKORN SH
BAKER B
Citation: Sh. Preskorn et B. Baker, FATALITY ASSOCIATED WITH COMBINED FLUOXETINE-AMITRIPTYLINE THERAPY, JAMA, the journal of the American Medical Association, 277(21), 1997, pp. 1682-1682
Authors:
PRESKORN SH
ALDERMAN J
GREENBLATT DJ
HORST WD
Citation: Sh. Preskorn et al., SERTRALINE DOES NOT INHIBIT CYTOCHROME-P450 3A-MEDIATED DRUG-METABOLISM IN-VIVO, Psychopharmacology bulletin, 33(4), 1997, pp. 659-665
Authors:
MAGNUS RD
FINDLING R
PRESKORN SH
FRIESEN S
MARCUS R
MARATHE P
DAMICO F
Citation: Rd. Magnus et al., AN OPEN-LABEL PHARMACOKINETIC TRIAL OF NEFAZODONE IN DEPRESSED CHILDREN AND ADOLESCENTS, Psychopharmacology bulletin, 33(3), 1997, pp. 550-550
Authors:
PRESKORN SH
HORST WD
ALDERMAN J
GREENBLATT DJ
Citation: Sh. Preskorn et al., SERTRALINE DOES NOT INHIBIT CYTOCHROME (CYP) 3A-MEDIATED DRUG-METABOLISM, Psychopharmacology bulletin, 33(3), 1997, pp. 573-573
Authors:
HARVEY AT
PRESKORN SH
Citation: At. Harvey et Sh. Preskorn, MECHANISM OF ACTION OF VENLAFAXINE IN NORMAL-MALE VOLUNTEERS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 41-41
Authors:
PRESKORN SH
OMO K
MAGNUS R
SHAD M
Citation: Sh. Preskorn et al., IMMEDIATE CROSSOVER FROM FLUOXETINE TO MIRTAZAPINE, Biological psychiatry, 41, 1997, pp. 331-331
Authors:
PRESKORN SH
Citation: Sh. Preskorn, TANDOSPIRONE, CNS DRUGS, 5(2), 1996, pp. 154-154
Authors:
CATTERSON ML
PRESKORN SH
Citation: Ml. Catterson et Sh. Preskorn, PHARMACOKINETICS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS - CLINICAL RELEVANCE, Pharmacology & toxicology, 78(4), 1996, pp. 203-208
Authors:
HARVEY AT
PRESKORN SH
Citation: At. Harvey et Sh. Preskorn, CYTOCHROME-P450 ENZYMES - INTERPRETATION OF THEIR INTERACTIONS WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS .2., Journal of clinical psychopharmacology, 16(5), 1996, pp. 345-355
Authors:
HARVEY AT
PRESKORN SH
Citation: At. Harvey et Sh. Preskorn, CYTOCHROME-P450 ENZYMES - INTERPRETATION OF THEIR INTERACTIONS WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS .1., Journal of clinical psychopharmacology, 16(4), 1996, pp. 273-285
Authors:
PRESKORN SH
Citation: Sh. Preskorn, DRUG-DRUG INTERACTIONS, The Journal of clinical psychiatry, 57(5), 1996, pp. 223-225
Authors:
PRESKORN SH
Citation: Sh. Preskorn, REDUCING THE RISK OF DRUG-DRUG INTERACTIONS - A GOAL OF RATIONAL DRUGDEVELOPMENT, The Journal of clinical psychiatry, 57, 1996, pp. 3-6
Authors:
BURKE MJ
CARMICHAEL C
HARVEY A
PRESKORN SH
Citation: Mj. Burke et al., THE PREVALENCE OF POLYPHARMACY AS A POTENTIAL RISK FOR DRUG-INTERACTIONS IN THE OUTPATIENT TREATMENT OF MAJOR DEPRESSION AND THE INPATIENT TREATMENT OF SCHIZOPHRENIA, Psychopharmacology bulletin, 32(3), 1996, pp. 419-419